KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Receivables - Other: 2009-2020

Historic Receivables - Other for Regeneron Pharmaceuticals (REGN) over the last 11 years, with Sep 2020 value amounting to $460.8 million.

  • Regeneron Pharmaceuticals' Receivables - Other rose 33.41% to $460.8 million in Q3 2020 from the same period last year, while for Sep 2020 it was $460.8 million, marking a year-over-year increase of 33.41%. This contributed to the annual value of $260.6 million for FY2019, which is 15.11% up from last year.
  • As of Q3 2020, Regeneron Pharmaceuticals' Receivables - Other stood at $460.8 million, which was up 18.40% from $389.2 million recorded in Q2 2020.
  • In the past 5 years, Regeneron Pharmaceuticals' Receivables - Other registered a high of $468.3 million during Q1 2020, and its lowest value of $93.0 million during Q4 2016.
  • In the last 3 years, Regeneron Pharmaceuticals' Receivables - Other had a median value of $269.3 million in 2018 and averaged $306.5 million.
  • As far as peak fluctuations go, Regeneron Pharmaceuticals' Receivables - Other crashed by 39.28% in 2016, and later spiked by 108.30% in 2017.
  • Quarterly analysis of 5 years shows Regeneron Pharmaceuticals' Receivables - Other stood at $93.0 million in 2016, then spiked by 108.30% to $193.7 million in 2017, then rose by 16.88% to $226.4 million in 2018, then increased by 15.11% to $260.6 million in 2019, then spiked by 33.41% to $460.8 million in 2020.
  • Its Receivables - Other stands at $460.8 million for Q3 2020, versus $389.2 million for Q2 2020 and $468.3 million for Q1 2020.